AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 15, 2026

Daily Signals

2696 companies scored · 2026-10-15 run in progress: 5121 of ~5380 signals so far · Total · absolute moveSwitch to Alpha · 30D 90D

Signal date 2026-10-15 Cut-offs from the 2026-10-15 run
Companies scored 2696 IC ≥ 0 · market cap ≥ $100M
Median forecast +2.60% Total · 90D
Long–short spread +5.95% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 429 ▼ 599 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

304 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
51 ALKSAlkermes plc. Life Sciences 0.44 $6.7B Unlock rating and forecasts
52 PRAXPraxis Precision Medicines, Inc. Life Sciences 0.42 $6.7B Unlock rating and forecasts
53 LNTHLantheus Holdings, Inc. Life Sciences 0.11 $6.5B Unlock rating and forecasts
54 IOVAIOVANCE BIOTHERAPEUTICS, INC. Life Sciences 0.40 $6.4B Unlock rating and forecasts
55 KNSAKiniksa Pharmaceuticals International, plc Life Sciences 0.00 $6.2B Unlock rating and forecasts
56 AMRXAmneal Pharmaceuticals, Inc. Life Sciences 0.49 $6.1B Neutral +1.03% +2.93% ·
57 LGNDLIGAND PHARMACEUTICALS INC Life Sciences 0.03 $5.9B Unlock rating and forecasts
58 IMVTImmunovant, Inc. Life Sciences 0.27 $5.8B Unlock rating and forecasts
59 CGONCG Oncology, Inc. Life Sciences 0.23 $5.5B Unlock rating and forecasts
60 MIRMMirum Pharmaceuticals, Inc. Life Sciences 0.05 $5.2B Unlock rating and forecasts
61 ERASErasca, Inc. Life Sciences 0.43 $5.1B Unlock rating and forecasts
62 KODKodiak Sciences Inc. Life Sciences 0.00 $5.1B Unlock rating and forecasts
63 ORKAOruka Therapeutics, Inc. Life Sciences 0.49 $5.1B Unlock rating and forecasts
64 TVTXTravere Therapeutics, Inc. Life Sciences 0.31 $5.0B Unlock rating and forecasts
65 PTCTPTC THERAPEUTICS, INC. Life Sciences 0.13 $5.0B Unlock rating and forecasts
66 COGTCogent Biosciences, Inc. Life Sciences 0.21 $4.9B Unlock rating and forecasts
67 CRSPCRISPR Therapeutics AG Life Sciences 0.30 $4.9B Unlock rating and forecasts
68 SRRKScholar Rock Holding Corp Life Sciences 0.21 $4.8B Unlock rating and forecasts
69 MANEVeradermics, Inc Life Sciences 0.20 $4.7B Unlock rating and forecasts
70 DFTXDefinium Therapeutics, Inc. Life Sciences 0.20 $4.6B Unlock rating and forecasts
71 DNTHDianthus Therapeutics, Inc. /DE/ Life Sciences 0.39 $4.2B Unlock rating and forecasts
72 ADPTAdaptive Biotechnologies Corp Life Sciences 0.16 $4.1B Unlock rating and forecasts
73 INDVIndivior Pharmaceuticals, Inc. Life Sciences 0.51 $4.0B Unlock rating and forecasts
74 EWTXEdgewise Therapeutics, Inc. Life Sciences 0.24 $4.0B Unlock rating and forecasts
75 ABCLAbCellera Biologics Inc. Life Sciences 0.35 $3.9B Unlock rating and forecasts
76 TNGXTango Therapeutics, Inc. Life Sciences 0.36 $3.7B Unlock rating and forecasts
77 RLAYRelay Therapeutics, Inc. Life Sciences 0.43 $3.7B Unlock rating and forecasts
78 OGNOrganon & Co. Life Sciences 0.44 $3.6B Unlock rating and forecasts
79 TLXTelix Pharmaceuticals Ltd Life Sciences 0.05 $3.6B Unlock rating and forecasts
80 LEGNLegend Biotech Corp Life Sciences 0.02 $3.5B Unlock rating and forecasts
81 AMLXAmylyx Pharmaceuticals, Inc. Life Sciences 0.31 $3.5B Unlock rating and forecasts
82 ACADACADIA PHARMACEUTICALS INC Life Sciences 0.39 $3.4B Unlock rating and forecasts
83 ARQTArcutis Biotherapeutics, Inc. Life Sciences 0.29 $3.3B Unlock rating and forecasts
84 XENEXenon Pharmaceuticals Inc. Life Sciences 0.44 $3.3B Unlock rating and forecasts
85 IDYAIDEAYA Biosciences, Inc. Life Sciences 0.30 $3.3B Unlock rating and forecasts
86 TARSTarsus Pharmaceuticals, Inc. Life Sciences 0.02 $3.2B Unlock rating and forecasts
87 LQDALiquidia Corp Life Sciences 0.14 $3.0B Unlock rating and forecasts
88 VKTXViking Therapeutics, Inc. Life Sciences 0.03 $3.0B Unlock rating and forecasts
89 ELVNEnliven Therapeutics, Inc. Life Sciences 0.43 $2.9B Unlock rating and forecasts
90 RCUSArcus Biosciences, Inc. Life Sciences 0.17 $2.9B Unlock rating and forecasts
91 RADXRadiopharm Theranostics Ltd Life Sciences 0.23 $2.6B Unlock rating and forecasts
92 NEOGNEOGEN CORP Life Sciences 0.36 $2.6B Unlock rating and forecasts
93 PGENPRECIGEN, INC. Life Sciences 0.31 $2.6B Unlock rating and forecasts
94 LIFEaTYR PHARMA INC Life Sciences 0.46 $2.5B Unlock rating and forecasts
95 NRIXNurix Therapeutics, Inc. Life Sciences 0.26 $2.5B Neutral +0.89% +2.84% ·
96 BEAMBeam Therapeutics Inc. Life Sciences 0.20 $2.4B Unlock rating and forecasts
97 ADMAADMA BIOLOGICS, INC. Life Sciences 0.26 $2.4B Unlock rating and forecasts
98 HCMHUTCHMED (China) Ltd Life Sciences 0.12 $2.4B Neutral +0.91% +2.75% ·
99 MBXMBX Biosciences, Inc. Life Sciences 0.07 $2.4B Unlock rating and forecasts
100 PBHPrestige Consumer Healthcare Inc. Life Sciences 0.28 $2.3B Unlock rating and forecasts
51–100 of 304 Previous Next
Since the previous run

Rating changes

▲ 429▼ 599
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected absolute price move over the horizon, market included. This is the number a price target is built from. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.